Resources to Empower Your Advocacy
We want to empower you to be an effective advocate in your local community, your state, and at the federal level. Below, you will find important documents about our advocacy work, such as relevant legislation, regulations, public comments, and educational information on prostate cancer. ZERO will update these documents regularly to serve as a library of relevant content to support your advocacy efforts.
Prostate Cancer Research Program at the Department of Defense
ZERO has prevented a cut to the Prostate Cancer Research Program (PCRP) in five out of the last seven years. Additionally, for the last eleven years, Congress has appropriated $80 million to the PCRP. However, in the FY2017 appropriations bill, Congress increased the PCRP’s funding to $90 million. We are pleased that through the efforts of ZERO Champions and the broader prostate cancer community, Congress is now funding the PCRP at its FY2001 level of $100 million. We urge Congress to reach new heights in the fight against prostate cancer by increasing the current funding level in the FY2020 appropriations process by $10M to $110M.
Get Involved with the PCRP
Congressional PCRP Sign-On Letters
- Fiscal Year 2020 Senate Sign-on Letter
- Fiscal Year 2020 House Sign-on Letter
- Fiscal Year 2019 Senate Sign-on Letter
- Fiscal Year 2019 House Sign-on Letter
- Fiscal Year 2018 Senate Sign-on Letter
- Fiscal Year 2018 House Sign-on Letter
- Fiscal Year 2017 Senate Sign-on Letter
- Fiscal Year 2017 House Sign-on Letter
Official ZERO Correspondence
The U.S. Preventive Services Task Force Prostate Cancer Screening Recommendations
On May 8, 2018, the USPSTF released their final recommendation for the prostate-specific antigen (PSA) screening, upgrading their recommendation from a “D” grade to a “C” grade. The “C” grade, while an improvement on their previous recommendations, it is still not sufficient because it means that insurance companies: 1) Do not have to cover the PSA-test and 2) Can make patients pay for all or some of the screening even if the insurance company does cover the test.
Official ZERO Correspondence
- May 8, 2018 – ZERO’s Official Press Release on the 2018 USPSTF Final Prostate Cancer PSA-based Screening “C” Reccommendation
- Prostate Cancer Community’s Joint Statement on the 2017 USPSTF Draft “C” Recommendation
- ZERO’s Official Press Release on the 2017 USPSTF Draft Prostate Cancer PSA-based Screening “C” Recommendation
- May 16, 2016 – Senate Health, Education, Labor, and Pensions (HELP) Committee Letter to Secretary of Health and Human Services (HHS)
- Initial Response from Secretary of HHS to Senate HELP Committee
- October 26, 2016 – Urology Policy Forum (UPF) Letter Supporting H.R. 1551 – The USPSTF Transparency and Accountability Act of 2015
- November 30, 2016 – ZERO’s Official Comments for the Congressional Record on the House Committee on Energy & Commerce’s Hearing: “Examining the United States Preventative Services Task Force”
Cancer Control and Prevention Funding at the Centers for Disease Control and Prevention (CDC)
CDC Prostate Cancer Resources
- Center for Disease Control and Prevention’s Prostate Cancer Overview
- CDC National Comprehensive Cancer Control Program (NCCCP)
Appropriations Reports
- 13,205M Recommended Funding in Senate Labor-HHS-Education Committee Fiscal Year 2019 Appropriations Report
- 13,205M Recommended Funding in House Labor-HHS-Education Committee Fiscal Year 2019 Appropriations Report
- $13M Recommended Funding in House Labor-HHS-Education Committee Fiscal Year 2018 Appropriations Report
- $13,205M Recommended Funding in Senate Labor-HHS-Education Committee Fiscal Year 2018 Appropriations Report
- $13M Recommended Funding in House Labor-HHS-Education Committee Fiscal Year 2017 Appropriations Report
- $13,205M Recommended Funding in Senate Labor-HHS-Education Committee Fiscal Year 2017 Appropriations Report
Coordinating Prostate Cancer Research Activities
To ensure best use of scarce federal dollars, aggressive pursuit of promising science, and coordination to support a wide range of priority research areas, ZERO advocates for the National Cancer Institute (NCI) to convene regular, public meetings of a prostate cancer research coordinating committee.
Prostate Cancer Activities at the National Cancer Institute (NCI)
- National Cancer Institute’s Prostate Cancer Overview
- NCI Budget and Appropriations
- Prostate Cancer Research Overview and Select Programs at NCI
- Prostate Cancer Research in the NCI Funded Research Portfolio
Appropriations Reports
- Senate Labor-HHS-Education Committee Fiscal Year 2019 Appropriations Report
- House Labor-HHS-Education Committee Fiscal Year 2019 Appropriations Report
- House Labor-HHS-Education Committee Fiscal Year 2018 Appropriations Report
- Senate Labor-HHS-Education Committee Fiscal Year 2018 Appropriations Report
- House Labor-HHS-Education Committee Fiscal Year 2017 Appropriations Report
- Senate Labor-HHS-Education Committee Fiscal Year 2017 Appropriations Report